3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn’s Disease 2016: Part 1: Diagnosis and Medical Management
2016 · Journal of Crohn s and Colitis · 2,044 citations
https://doi.org/10.1093/ecco-jcc/jjw168
F
Fernando Rizzello
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola(IT)
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
376
Papers
13.6K
Citations
50
h-index
145
i10-index
Fernando Rizzello is an academic researcher from IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola. The author has contributed to research in topics: Inflammatory Bowel Disease & Microscopic Colitis & Celiac Disease Research and Management. The author has an h-index of 50, co-authored 320 publications.
ORCID: 0000-0002-7949-5362Papers by this author
worksParental Bonding and Inflammatory Bowel Disease
2010 · Psychosomatics · 31 citations
https://doi.org/10.1176/appi.psy.51.1.14
Dietary geraniol ameliorates intestinal dysbiosis and relieves symptoms in irritable bowel syndrome patients: a pilot study
2018 · BMC Complementary and Alternative Medicine · 29 citations
https://doi.org/10.1186/s12906-018-2403-6
Selective cyclooxygenase-2 silencing mediated by engineered E. coli and RNA interference induces anti-tumour effects in human colon cancer cells
2010 · British Journal of Cancer · 17 citations
https://doi.org/10.1038/sj.bjc.6605859
Effectiveness of adalimumab for ulcerative colitis: A multicentre, retrospective study of clinical practice in Italy
2021 · Digestive and Liver Disease · 7 citations
https://doi.org/10.1016/j.dld.2021.08.020
Poor prognostic factors of pharmacokinetic origin predict outcomes in inflammatory bowel disease patients treated with anti-tumor necrosis factor-α
2024 · Frontiers in Immunology · 4 citations
https://doi.org/10.3389/fimmu.2024.1342477
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat